DOM-CR

DOM-CR
Clinical data
Other names	DOM/CR; "DOM-Conformationally Restrained"; 5,8-Dimethoxy-7-methyl-THIQ; DOM-THIQ; DOM/THIQ
Identifiers
	IUPAC name 5,8-dimethoxy-7-methyl-1,2,3,4-tetrahydroisoquinoline;
CAS Number	228997-46-4;
PubChem CID	10198181;
ChemSpider	8373681;
Chemical and physical data
Formula	C12H17NO2
Molar mass	207.273 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC(=C2CCNCC2=C1OC)OC;
	InChI InChI=1S/C12H17NO2/c1-8-6-11(14-2)9-4-5-13-7-10(9)12(8)15-3/h6,13H,4-5,7H2,1-3H3; Key:LDSXYNSFNYUAHP-UHFFFAOYSA-N;

DOM-CR, or DOM/CR, an acronym of "DOM-conformationally restrained", is a tetrahydroisoquinoline (THIQ) and cyclized phenethylamine related to the psychedelics DOM and 2C-D. It is a cyclized THIQ analogue of DOM and 2C-D.

DOM-CR shows more than 20-fold reduced affinity for the serotonin 5-HT_2A receptor compared to DOM (K_i = 2,150 nM vs. 100 nM, respectively). In contrast to DOM, DOM-CR does not substitute for DOM in rodent drug discrimination tests, suggesting that it lacks psychedelic effects. Similarly, DOM-CR does not substitute for dextroamphetamine or MDMA, suggesting that it likewise lacks stimulant or entactogenic effects. However, DOM-CR does substitute for TDIQ (MDTHIQ), a selective α₂-adrenergic receptor ligand. At high doses, DOM-CR produces behavioral disruption in drug discrimination tests. In contrast to DOM and amphetamine, DOM-CR does not produce hyperlocomotion in rodents.

DOM-CR was first described in the scientific literature by Richard Glennon and colleagues by 1996.